

CLAIMS

We Claim:

1. A preventive agent for carcinogenesis of liver cancer, comprising
5 menatetrenone as an active ingredient.
2. A preventive agent for carcinogenesis of cancer derived from chronic
liver disease, comprising menatetrenone as an active ingredient.
- 10 3. A preventive agent for carcinogenesis of liver cancer derived from
cirrhosis, comprising menatetrenone as an active ingredient.
4. A preventive agent for carcinogenesis of liver cancer derived from
hepatitis virus cirrhosis, comprising menatetrenone as an active ingredient.
15
5. A preventive agent for carcinogenesis of liver cancer derived from
hepatitis C virus cirrhosis, comprising menatetrenone as an active ingredient.
6. A method for preventing carcinogenesis of liver cancer, comprising
20 administering menatetrenone.
7. A method for preventing carcinogenesis of cancer derived from chronic
liver disease, comprising administering menatetrenone.
- 25 8. A method for preventing carcinogenesis of live cancer derived from
chronic liver disease, comprising administering menatetrenone.
9. A method for preventing carcinogenesis of live cancer derived from
hepatitis virus cirrhosis, comprising administering menatetrenone.
30
10. A method for preventing carcinogenesis of live cancer derived from
hepatitis C virus cirrhosis, comprising administering menatetrenone.

11. A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer.

5 12. A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of cancer derived from chronic liver disease.

13. A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer derived from cirrhosis.

10 14. A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer derived from hepatitis virus cirrhosis.

15 15. A use of menatetrenone for the manufacture of a preventive agent for carcinogenesis of liver cancer derived from hepatitis C virus cirrhosis.